As is well known, immunological control of CMV infection requires permanent immune surveillance, particularly with an increase of up to 10%–30% of CMV-specific CD8+ T cells in the periphery, which remains to elevate over time. The gene discussed is CD8A; the disease is cytomegalovirus infection.